Maravai LifeSciences Sees Unusually Large Options Volume (NASDAQ:MRVI)

Key Points

• Maravai LifeSciences experienced a significant surge in options trading, with a reported increase of approximately 1,791% in put options volume on Wednesday.
• The company's stock opened at $3.37 and has a market capitalization of $860.56 million, with a recent 1-year low of $1.66.
• Analysts have mixed views on MRVI, with a consensus rating of "Hold" and a reduced average price target of $5.22.

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Traders bought 1,002 put options on the company. This represents an increase of approximately 1,791% compared to the typical daily volume of 53 put options.

Maravai LifeSciences Trading Up 4.3%

Shares of Maravai LifeSciences stock opened at $3.37 on Thursday. The company's fifty day simple moving average is $2.70 and its 200-day simple moving average is $2.39. The stock has a market capitalization of $860.56 million, a PE ratio of -2.48 and a beta of 0.33. Maravai LifeSciences has a 1-year low of $1.66 and a 1-year high of $8.53. The company has a debt-to-equity ratio of 0.68, a current ratio of 5.16 and a quick ratio of 4.49.

Institutional Trading of Maravai LifeSciences

Several institutional investors and hedge funds have recently modified their holdings of MRVI. Teacher Retirement System of Texas bought a new stake in shares of Maravai LifeSciences during the 1st quarter valued at $37,000. VELA Investment Management LLC increased its holdings in Maravai LifeSciences by 5.6% in the 1st quarter. VELA Investment Management LLC now owns 156,334 shares of the company's stock valued at $345,000 after acquiring an additional 8,222 shares during the last quarter. Pekin Hardy Strauss Inc. bought a new stake in Maravai LifeSciences in the 1st quarter valued at $55,000. Royce & Associates LP increased its holdings in Maravai LifeSciences by 38.5% in the 1st quarter. Royce & Associates LP now owns 1,328,444 shares of the company's stock valued at $2,936,000 after acquiring an additional 369,559 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Maravai LifeSciences by 56.2% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 47,031 shares of the company's stock valued at $104,000 after acquiring an additional 16,914 shares during the last quarter. 50.25% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

MRVI has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Maravai LifeSciences in a report on Tuesday. Royal Bank Of Canada cut their price target on shares of Maravai LifeSciences from $7.00 to $5.00 and set an "outperform" rating on the stock in a report on Tuesday, August 12th. Three analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $5.22.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.